

ASX ANNOUNCEMENT

17 August 2023

Shareholder update webinar

17 August 2023 – Cann Group Limited (ASX: CAN) (**Cann** or the **Company**) is pleased to invite shareholders, investors and interested parties to an investor update webinar and Q&A with CEO, Peter Koetsier to outline the Company's FY23 results.

The webinar will be held on **Monday, 28 August 2023 at 11:00 am** (Melbourne, Australia time).

Anyone wishing to attend the webinar is invited to register at the following link:

https://us02web.zoom.us/webinar/register/WN_pQ57h89FQP2GHneoe4hpZA

After registering, you will receive a confirmation email containing information about joining the webinar.

Shareholders are encouraged to participate in this webinar by submitting questions in advance to:

contact@canngrouponlimited.com

A recording of the webinar will be available on the Company's website shortly after the live session.

Authorised for release by Deborah Ambrosini, Company Secretary, Cann Group Limited.

For all media enquiries please contact:

Jackson Paine
Corporate Communications Manager
+61 439 492 955
jackson.paine@canngrouponlimited.com

For all other information please contact:

Peter Koetsier
CEO
Cann Group Limited
+61 3 9095 7088
contact@canngrouponlimited.com

Deborah Ambrosini
CFO
Cann Group Limited
+61 3 9095 7088
deborah.ambrosini@canngrouponlimited.com

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is enhancing patients' lives by developing, producing, and supplying innovative cannabis medicines. The Company has research facilities and corporate headquarters in Melbourne and operates a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology.

Learn more at: www.canngrouponlimited.com | www.satipharm.com